莫西沙星与司帕沙星对耐多药肺结核病的临床观察  

Therapeutic effects of moxifloxacin and sparfloxicin on multiple drug resistant pulmonary tuberculosis

作　　者：张向丛[1] 张笑丹[1] 王淑平[1] 邵艳欣[1] 孙彦军[1] 白云[1] 蔡兰英[1] 张俊萍[1] 赵静茹[1] 

机构地区：[1]河北省胸科医院,石家庄市050041

出　　处：《河北医药》2007年第8期796-798,共3页Hebei Medical Journal

基　　金：河北省卫生厅计划项目(编号062761918)

摘　　要：目的评价新一代氟喹诺酮类药物（FQNs）莫西沙星（MXFX）对耐多药肺结核病（MDR-PTB）的临床疗效及安全性。方法将MDR-PTB患者随机分为两组,治疗组用含MXFX方案,对照组用含司帕沙星（SPFX）方案,疗程12个月。结果满疗程时可以评价疗效的治疗组36例、对照组35例。满2-3个月时痰菌阴转率达到75.0%、80.3%,对照组为51.4%、68.6%,2组比较差异显著（P〈0.05）,4个月以后各期痰菌阴转率也均高于对照组,但经统计学处理差异无显著性（P〉0.05）。疗程末治疗组痰菌阴转率、病灶吸收、空洞闭合率分别为91.7%、88.9%、54.5%,均高于对照组相应指标82.9%、80.0%、40.6%,但2组比较差异无显著性（P〉0.05）,药物不良反应治疗组15.4%,低于对照组35.0%,经统计学处理差异显著（P〈0.05）。结论MXFX是一种安全、有效的抗MDR-PTB的药物。Objective To compare and evaluate the therapeuficeffect and safety of moxifloxacin on multiple drug resistant pulmonary tuberculosis（MDR-PTB）. Methods 81 patients with MDR-PTB were randomlydivided into trial group and eantrol group. The patients in trial group were treated with moxifloxacin containing regimen; the patients in control group were treated with sparfloxacin-containing regimen, with a treatment course of 12 months foforboth groups.Results At the end of the treatment course,36 patients in trial group and 35 patients in control group could he evaluated. In full of 2 and 3 months, the sputums negative conversion rates were 75 %, 80.3 % in trialgroup, which were significantly higher than 51.4%, 60.0% i control group （ P 〈 0.05）, Four months later, the sputum negativeconversion rotes in trial group were higher than those of control group, but there was no significant difference hetween the two groups （ P 〉 0.05）. At end of treatment course, the sputums negative conversion rate, focus absorption rate and cavity closing rate were 91.7%, 88.9%, 54.5% respectively in trial group, which were significantly higher than 82.9%, 80.0. %, 40.6% in control group （ P 〉 0.05）, but theree were no significant differences between two groups （ P 〉 0.05）. Adverse reaction intrial group was 15.4%, which was significantly lower than 35.0% in control group（ P 〈 0.05）. Conclusion Moxiflocacin-containing regimen is effective and safe drug in the treatment of MDR-PTB.

关 键 词：莫西沙星 司帕沙星 耐多的肺结核病 临床疗效 

分 类 号：R521[医药卫生—内科学]